Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients.

OBJECTIVE To evaluate at 9 months and 24 months the safety and efficacy of intravenous immunoglobulins (IVIGs) administered for 6 months to treat relapses of Wegener's granulomatosis (WG) or microscopic polyangiitis (MPA) occurring either under treatment or during the year following discontinuation of corticosteroids and/or immunosuppressants. METHODS Patients received IVIGs (0.5 gm/kg/day for 4 days) as additional therapy administered monthly for 6 months and were assessed every 3-6 months. Corticosteroids could be maintained or reintroduced at the time of relapse; immunosuppressants could be continued but could not be reintroduced. At months 9 (end point) and 24 (followup), the following information was collected: complete or partial remission, relapse as assessed with the Birmingham Vasculitis Activity Score (BVAS) 2005, and tolerance and safety of IVIG therapy. RESULTS Twenty-two Caucasian patients (7 men and 15 women) were studied: 19 had WG, and 3 had MPA. Their median age was 53 years (range 19-75 years), and their median duration of systemic vasculitis was 27 months (range 7-109 months). Their median BVAS 2005 score was 11 (range 3-25). At study entry, 21 patients were ANCA positive, and 21 patients were taking steroids and/or immunosuppressants. All patients experiencing relapse were treated with the same drug(s) plus IVIGs. All patients initially responded to IVIG therapy. By month 9, 13 patients had complete remission, 1 had partial remission, 7 had relapse, and 1 had treatment failure. In 8 of the 14 patients who had remission, the response persisted at month 24. Seven patients experienced minor side effects. CONCLUSION IVIGs induced complete remissions of relapsed ANCA-associated vasculitides in 13 of 22 patients at month 9. Because of the good safety and tolerance profiles of IVIGs, these agents can be included in a therapeutic strategy with other drugs used to treat relapses of WG or MPA.

[1]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). , 2010, Arthritis and rheumatism.

[2]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. , 2010, Arthritis and rheumatism.

[3]  C. Pagnoux.  [Wegener's granulomatosis and microscopic polyangiitis]. , 2008, La Revue du praticien.

[4]  C. Kempf,et al.  Virus safety of intravenous immunoglobulin , 2005, Clinical reviews in allergy & immunology.

[5]  P. Aries,et al.  Intravenous immunoglobulin therapy in vasculitis , 2005, Clinical reviews in allergy & immunology.

[6]  Y. Shoenfeld,et al.  Intravenous immunoglobulin , 2005, Clinical reviews in allergy & immunology.

[7]  J. Krischer,et al.  Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. , 2005, The Journal of rheumatology.

[8]  Jianwen Cai,et al.  Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic AntibodyAssociated Small-Vessel Vasculitis , 2005, Annals of Internal Medicine.

[9]  T. Kita,et al.  Clinical Efficacy of Intravenous Immunoglobulin for Patients with MPO-ANCA-Associated Rapidly Progressive Glomerulonephritis , 2005, Nephron Clinical Practice.

[10]  C. Feighery,et al.  Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. , 2005, Arthritis and rheumatism.

[11]  G. Danieli,et al.  Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome , 2004, Annals of the rheumatic diseases.

[12]  Y. Shoenfeld,et al.  Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis , 2003, Annals of the rheumatic diseases.

[13]  P. Lamprecht,et al.  Maintenance of remission with leflunomide in Wegener's granulomatosis. , 2003, Rheumatology.

[14]  V. Tesar,et al.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. , 2003, The New England journal of medicine.

[15]  C. Langford,et al.  Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. , 2003, The American journal of medicine.

[16]  L. Mouthon,et al.  Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. , 2003, Arthritis and rheumatism.

[17]  K. De Groot,et al.  High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. , 2002, Arthritis and rheumatism.

[18]  D. Adu,et al.  The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  S. Kaveri,et al.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.

[20]  L. Rauova,et al.  Adverse Effects of Intravenous Immunoglobulin Therapy in 56 Patients with Autoimmune Diseases , 2001, Pharmacology.

[21]  C. Langford,et al.  Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. , 2000, Arthritis and rheumatism.

[22]  D. Adu,et al.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. , 2000, QJM : monthly journal of the Association of Physicians.

[23]  M. Heller,et al.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. , 2000, Arthritis and rheumatism.

[24]  K. Andrassy,et al.  Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. , 1999, Journal of the American Society of Nephrology : JASN.

[25]  Y. Shoenfeld,et al.  Serologic and Clinical Response to Treatment of Systemic Vasculitis and Associated Autoimmune Disease with Intravenous Immunoglobulin , 1999, International Archives of Allergy and Immunology.

[26]  M. Ishii,et al.  Selective high dose gamma‐globulin treatment in Kawasaki disease: Assessment of clinical aspects and cost effectiveness , 1999, Pediatrics international : official journal of the Japan Pediatric Society.

[27]  B. Hoen,et al.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. , 1997, Arthritis and rheumatism.

[28]  J. Larson.  The MOS 36-Item Short form Health Survey , 1997, Evaluation & the health professions.

[29]  D. Jayne,et al.  Intravenous immunoglobulin as sole therapy for systemic vasculitis. , 1996, British journal of rheumatology.

[30]  C. Kallenberg,et al.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis , 1996 .

[31]  W. Gross,et al.  Treatment of anti‐neutrophil cytoplasmic antibody (ANCA)‐associated systemic vasculitis with high‐dose intravenous immunoglobulin , 1995, Clinical and experimental immunology.

[32]  R. Porter.  Nomenclature of Systemic Vasculitides: Proposal of an International Consensus Conference , 1995 .

[33]  R. Moots,et al.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.

[34]  C. Sherbourne,et al.  The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. , 1994 .

[35]  D. Jayne,et al.  ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. , 1993, Journal of autoimmunity.

[36]  Guy Hoffman,et al.  The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. , 1992, Arthritis and rheumatism.

[37]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[38]  M. Davies,et al.  Treatment of systemic vasculitis with pooled intravenous immunoglobulin , 1991, The Lancet.

[39]  T. H. The,et al.  AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.

[40]  J. Stone.  Etanercept plus Standard Therapy for Wegener's Granulomatosis , 2005 .

[41]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .

[42]  O. Lortholary,et al.  Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. , 1996, Medicine.

[43]  D. Jayne,et al.  Pooled intravenous immunoglobulin in the management of systemic vasculitis. , 1993, Advances in experimental medicine and biology.